Related Experiment Videos
Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced
Bernhard Richter1, Kathrin Rychli, Philipp J Hohensinner
1Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Objective:
To assess the prognostic value of the pro-apoptotic, but also cell growth-inducing molecule soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) in heart failure (HF).
Methods:
We assayed sTWEAK levels in 351 patients with advanced HF (non-ischemic: 130, ischemic: 221). During a median follow-up of 4.9 years, 195 patients (56%) died.
Results:
sTWEAK concentrations were associated with extended survival in patients with non-ischemic (P=0.022), but not with ischemic HF (P=0.82). The inverse association in non-ischemic HF remained significant in a multivariable Cox regression model (P=0.025) with a hazard ratio of 0.40 (95% confidence interval: 0.21-0.77) comparing the third to the first tertile (P=0.007).
Conclusion:
Low sTWEAK levels independently predict mortality in advanced non-ischemic HF. sTWEAK-induced proliferation of cardiomyocytes may explain its impact on suvival. The different prognostic value of sTWEAK in ischemic and non-ischemic HF may point towards distinct pathogenic pathways determining the course of disease.
Related Concept Videos
Heart Failure II: Pathophysiology
Heart Failure IV: Classification and Diagnostic Evaluation
Pathophysiology of Heart Failure
Heart Failure III: Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies
Heart Failure Drugs: Inotropic Agents